3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Myeloproliferative Disorders
2
Leukemia, Myelomonocytic, Chronic
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Esophageal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Rituximab
41
Cyclophosphamide
23
Peripheral Blood Stem Cell Transplantation
15
Lenalidomide
14
ibrutinib
11
fludarabine phosphate
11
Etoposide
10
Bortezomib
10
Filgrastim
9
Bendamustine Hydrochloride
9
Mycophenolic Acid
8
Melphalan
8
Cytarabine
8
venetoclax
7
fludarabine
7
Whole-Body Irradiation
7
Vincristine
7
Cyclosporine
7
CT-P10
7
Methotrexate
6
obinutuzumab
5
acalabrutinib
5
Doxorubicin
5
Carmustine
5
Carboplatin
5
Biopsy
5
pembrolizumab
4
ibritumomab tiuxetan
4
carmustine, poliferprosan 20 drug combination
4
Tacrolimus
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Lymphoma, Mantle-Cell
×
eprenetapopt
×
Clear all
NCT04419389
2025-03-17
R/R
Aprea Therapeutics
Phase 1/2
Terminated
1 enrolled
4 charts